Burke T J, Malhotra D, Shapiro J I
Department of Medicine, University of Colorado School of Medicine, Denver, Ohio, USA.
Kidney Int. 2001 Oct;60(4):1407-14. doi: 10.1046/j.1523-1755.2001.00968.x.
Acute renal failure is believed to be caused, in some circumstances, by impaired oxygen delivery to the outer medulla. This study examined the effect of RSR13, a synthetic allosteric modifier of hemoglobin oxygen-binding affinity, on renal function in a setting of acute renal failure in rats.
An in vivo model of acute renal failure in the rat produced by reduced renal mass, salt restriction, volume depletion, prostaglandin inhibition, and radiocontrast administration was used. A computer-based simulation of oxygen tensions along the nephron was utilized to interpret the findings. Mechanistic studies were subsequently performed using oxygen-sensitive electrodes and 31P nuclear magnetic resonance (NMR) spectroscopy to define the effect of RSR13 on renal function in the setting of compromised acute renal failure.
RSR13 did not attenuate acute renal failure in this model; rather, serum creatinine increased to a greater degree in the RSR13-treated rats than in rats receiving saline vehicle as the control (P < 0.05). Simulations explained this finding under conditions of severe medullary hypoxia. Mechanistic studies demonstrated marked worsening of medullary hypoxia following RSR13 under conditions similar to our experimental model. Furosemide pretreatment to reduce the imbalance between oxygen supply and demand markedly attenuated the basal-medullary hypoxia produced in the presence of indomethacin and RSR13 (P < 0.01). Additionally, 31P NMR studies demonstrated renal adenosine 5'-triphosphate (ATP) depletion in rats with acute renal failure treated with RSR13 (45% decrease, P < 0.01); again, this effect of RSR13 was completely prevented by pretreatment with furosemide.
Under conditions of severe renal medullary hypoxia, induced in part by indomethacin-mediated reductions in outer medullary blood flow, the administration of RSR13 can exacerbate acute renal dysfunction. However, reducing the rate of oxygen consumption by inhibiting sodium transport with furosemide pretreatment or post-treatment appears to be functionally protective.
在某些情况下,急性肾衰竭被认为是由外髓质氧输送受损所致。本研究检测了血红蛋白氧结合亲和力的合成变构调节剂RSR13对大鼠急性肾衰竭时肾功能的影响。
采用减少肾质量、限制盐摄入、容量耗竭、抑制前列腺素和给予放射性造影剂建立大鼠急性肾衰竭体内模型。利用基于计算机的沿肾单位氧张力模拟来解释研究结果。随后使用氧敏感电极和31P核磁共振(NMR)光谱进行机制研究,以确定RSR13在急性肾衰竭受损情况下对肾功能的影响。
在该模型中,RSR13并未减轻急性肾衰竭;相反,与接受生理盐水作为对照的大鼠相比,接受RSR13治疗的大鼠血清肌酐升高幅度更大(P<0.05)。模拟结果解释了在严重髓质缺氧条件下的这一发现。机制研究表明,在与我们实验模型相似的条件下,RSR13给药后髓质缺氧明显恶化。用呋塞米预处理以减少供需失衡,可显著减轻吲哚美辛和RSR13存在时产生的基底髓质缺氧(P<0.01)。此外,31P NMR研究表明,接受RSR13治疗的急性肾衰竭大鼠肾腺苷5'-三磷酸(ATP)耗竭(降低45%,P<0.01);同样地呋塞米预处理可完全预防RSR13的这一作用。
在由吲哚美辛介导的外髓质血流减少部分诱导的严重肾髓质缺氧条件下,给予RSR13可加重急性肾功能障碍。然而,通过呋塞米预处理或后处理抑制钠转运来降低氧消耗率似乎具有功能保护作用。